跳至主要内容
临床试验/JPRN-UMIN000048463
JPRN-UMIN000048463已完成未知

A Prospective Study to Evaluate Effectiveness of Upadacitinib in Moderate to Severe AD with Prurigo Nodules in the Real World in Japan - ADMIRE

AbbVie GK0 个研究点目标入组 200 人开始时间: 2022年7月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
AbbVie GK
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients who had prior treatment with Upadacitinib 2.Patients who have contraindications to Upadacitinib 3. Patients who have chronic pruritus resulting from another condition (e.g.,neuropathic disorders) than AD, prurigo nodules 4. Patients who have prurigo nodules caused by medication, metal allergy, infection, insect bite 5. Patients who are currently participating in interventional research or participated within 30 days (not including another post-marketing observational study, or registry participation).

研究者

发起方
AbbVie GK

相似试验